Tuesday, December 22, 2020

Neomorph Finds $109M

San Diego-based Neomorph, a biotech startup focused on protein degradation, said today that it has raised $109M in a Series A funding. The funding came from Deerfield Management. The company said its targeted protein degradation technology is aimed at developing novel therapeutics across a broad range of disease areas, including oncology. The company's scientific founders are Phil Chamberlain, DPhil; Eric Fischer, PhD; Benjamin Ebert, MD, PhD; and Scott Armstrong, MD, PhD. The company said it will use the Series A funding to further develop its platform, advance lead programs, and expand the research team.